Skip to main content
SpringerLink
Log in

Hepatic Artery Infusion Therapy for Primary Liver Tumors

  • Chapter
  • First Online:
Book cover Primary and Metastatic Liver Tumors

  • 590 Accesses

Abstract

Hepatic artery infusion (HAI) therapy for primary liver cancers appears to prolong survival in select candidates with advanced, locoregional disease. A typical candidate is a patient with advanced disease confined to the liver in whom resection, transplantation, and/or ablative therapies are contraindicated due to the extent of disease, recurrence risk, or involvement of hepatic vasculature. For hepatocellular carcinoma, the best evidence supporting HAI therapy involves the utilization of intra-arterial 5-FU with or without cisplatin, often in conjunction with intramuscular or subcutaneous IFN-α. Patients with concomitant cirrhosis tend to have worse outcomes, while those with hepatitis C have a better prognosis if treated with ribavirin.

For cholangiocarcinoma, HAI therapy appears to confer a survival advantage, but evidence is limited to case series, and the wide variety of regimens employed precludes any definitive conclusions regarding optimal therapy.

Toxicities depend on the chemotherapeutic agents used but most commonly involve cytopenias or elevation in liver function tests, which almost never require intervention. Though rare, serious complications such as hepatic decompensation or cholangitis can be fatal. Technical complications related to the device are uncommon and can usually be resolved with replacement.

Routine cross-sectional imaging should be performed to assess response to therapy. Patients with exceptional responses may become eligible for other therapies such as resection or ablation, while nonresponders should be triaged to alternative chemotherapeutic agents or other treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312–37.

    Article  PubMed  Google Scholar 

  2. Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol. 2006;23(1):47–63.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology (Baltimore MD). 2001;33(6):1353–7.

    Article  CAS  Google Scholar 

  4. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Nakajima T, Kondo Y, Miyazaki M, Okui K. A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading. Hum Pathol. 1988;19(10):1228–34.

    Article  CAS  PubMed  Google Scholar 

  6. Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K. Pathologic and radiographic studies of intrahepatic metastasis in hepatocellular carcinoma; the role of efferent vessels. HPB Surg. 1996;10(2):97–103; discussion -4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sullivan RD, Miller E, Sikes MP. Antimetabolite-metabolite combination cancer chemotherapy. Effects of intraarterial methotrexate-intramuscular Citrovorum factor therapy in human cancer. Cancer. 1959;12:1248–62.

    Article  CAS  PubMed  Google Scholar 

  8. Sullivan RD, Norcross JW, Watkins E Jr. Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion. N Engl J Med. 1964;270:321–7.

    Article  CAS  PubMed  Google Scholar 

  9. Fortner JG, Mulcare RJ, Solis A, Watson RC, Golbey RB. Treatment of primary and secondary liver cancer by hepatic artery ligation and infusion chemotherapy. Ann Surg. 1973;178(2):162–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bern MM, W MD Jr, Cady B, Oberfield RA, Trey C, Clouse ME, et al. Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report. Cancer. 1978;42(2):399–405.

    Article  CAS  PubMed  Google Scholar 

  11. Bhutiani N, Martin RC 2nd. Transarterial therapy for colorectal liver metastases. Surg Clin North Am. 2016;96(2):369–91.

    Article  PubMed  Google Scholar 

  12. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology. 1995;52(4):295–9.

    Article  CAS  PubMed  Google Scholar 

  13. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 2002;94(2):435–42.

    Article  CAS  PubMed  Google Scholar 

  14. Hamada A, Yamakado K, Nakatsuka A, Takaki H, Akeboshi M, Takeda K. Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors. J Vasc Interv Radiol. 2004;15(8):835–41.

    Article  PubMed  Google Scholar 

  15. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer. 2005;93(5):557–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Yamasaki T, Kimura T, Kurokawa F, Aoyama K, Ishikawa T, Tajima K, et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol. 2005;40(1):70–8.

    Article  CAS  PubMed  Google Scholar 

  17. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006;106(9):1990–7.

    Article  CAS  PubMed  Google Scholar 

  18. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee DY, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(1):129–37.

    Article  PubMed  Google Scholar 

  19. Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2007;42(10):845–53.

    Article  CAS  PubMed  Google Scholar 

  20. Kasai K, Kuroda H, Ushio A, Sawara K, Takikawa Y, Suzuki K. Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion: preliminary results. Hepatol Res. 2009;39(2):117–25.

    Article  CAS  PubMed  Google Scholar 

  21. Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, et al. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol. 2009;44(5):492–502.

    Article  CAS  PubMed  Google Scholar 

  22. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology. 2010;78 Suppl 1:148–53.

    Article  PubMed  Google Scholar 

  23. Woo HY, Bae SH, Park JY, Han KH, Chun HJ, Choi BG, et al. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2010;65(2):373–82.

    Article  CAS  PubMed  Google Scholar 

  24. Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, et al. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma. Int J Clin Oncol. 2011;16(3):221–9.

    Article  CAS  PubMed  Google Scholar 

  25. Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, et al. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology. 2011;81(5–6):281–90.

    Article  CAS  PubMed  Google Scholar 

  26. Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer. 2013;109(7):1904–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50(4):445–54.

    Article  CAS  PubMed  Google Scholar 

  28. Enjoji M, Morizono S, Kotoh K, Kohjima M, Miyagi Y, Yoshimoto T, et al. Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. World J Gastroenterol: WJG. 2005;11(36):5685–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ikeda M, Okusaka T, Ueno H, Morizane C, Iwasa S, Hagihara A, et al. Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. Oncology. 2007;72(3–4):188–93.

    Article  CAS  PubMed  Google Scholar 

  30. Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Ogura T, et al. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization. Cancer Chemother Pharmacol. 2008;61(4):683–8.

    Article  CAS  PubMed  Google Scholar 

  31. Tommasini M, Colombo M, Sangiovanni A, Orefice S, Bignami P, Doci R, et al. Intrahepatic doxorubicin in unresectable hepatocellular carcinoma. The unfavorable role of cirrhosis. Am J Clin Oncol. 1986;9(1):8–11.

    Article  CAS  PubMed  Google Scholar 

  32. Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2003;9(12):2666–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, et al. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol. 2007;13(41):5465–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–62.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.

    Article  PubMed  Google Scholar 

  36. Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689–700.

    Article  PubMed  Google Scholar 

  37. Spolverato G, Kim Y, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol. 2016;23(1):235–43.

    Article  PubMed  Google Scholar 

  38. Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg. 1998;228(3):385–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Chamberlain RS, Blumgart LH. Hilar cholangiocarcinoma: a review and commentary. Ann Surg Oncol. 2000;7(1):55–66.

    Article  CAS  PubMed  Google Scholar 

  40. Launois B, Reding R, Lebeau G, Buard JL. Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepato-Biliary-Pancreat Surg. 2000;7(2):128–34.

    Article  CAS  Google Scholar 

  41. Nagino M, Nimura Y, Kamiya J, Kanai M, Uesaka K, Hayakawa N, et al. Segmental liver resections for hilar cholangiocarcinoma. Hepato-Gastroenterology. 1998;45(19):7–13.

    CAS  PubMed  Google Scholar 

  42. Nakeeb A, Tran KQ, Black MJ, Erickson BA, Ritch PS, Quebbeman EJ, et al. Improved survival in resected biliary malignancies. Surgery. 2002;132(4):555–63; discussion 63-4.

    Article  PubMed  Google Scholar 

  43. Rea DJ, Munoz-Juarez M, Farnell MB, Donohue JH, Que FG, Crownhart B, et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg (Chicago, IL: 1960). 2004, 139;(5):514. 23; discussion 23-5

    Google Scholar 

  44. Tsao JI, Nimura Y, Kamiya J, Hayakawa N, Kondo S, Nagino M, et al. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg. 2000;232(2):166–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg (Chicago IL : 1960). 1995;130(3):270–6.

    CAS  Google Scholar 

  46. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242(3):451–8. discussion 8-61

    PubMed  PubMed Central  Google Scholar 

  47. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

    Article  CAS  PubMed  Google Scholar 

  48. Huitzil-Melendez FD, O'Reilly EM, Duffy A, Abou-Alfa GK. Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancers. Surg Oncol Clin N Am. 2009;18(2):361–79. x

    Article  PubMed  Google Scholar 

  49. Tanaka N, Yamakado K, Nakatsuka A, Fujii A, Matsumura K, Takeda K. Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma--initial experience. Eur J Radiol. 2002;41(1):42–8.

    Article  PubMed  Google Scholar 

  50. Mambrini A, Guglielmi A, Pacetti P, Iacono C, Torri T, Auci A, et al. Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Res. 2007;27(4c):3009–13.

    CAS  PubMed  Google Scholar 

  51. Shitara K, Ikami I, Munakata M, Muto O, Sakata Y. Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma. Clin Oncol (R Coll Radiol). 2008;20(3):241–6.

    Article  CAS  Google Scholar 

  52. Jarnagin WR, Schwartz LH, Gultekin DH, Gonen M, Haviland D, Shia J, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol. 2009;20(9):1589–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Kemeny NE, Schwartz L, Gonen M, Yopp A, Gultekin D, D'Angelica MI, et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology. 2011;80(3–4):153–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Sinn M, Nicolaou A, Gebauer B, Podrabsky P, Seehofer D, Ricke J, et al. Hepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase II study. Dig Dis Sci. 2013;58(8):2399–405.

    Article  CAS  PubMed  Google Scholar 

  55. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, et al. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013;4(1):156–65.

    Article  PubMed  Google Scholar 

  56. Ghiringhelli F, Lorgis V, Vincent J, Ladoire S, Guiu B. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience. Chemotherapy. 2013;59(5):354–60.

    Article  CAS  PubMed  Google Scholar 

  57. Massani M, Nistri C, Ruffolo C, Bonariol R, Pauletti B, Bonariol L, et al. Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience. Updat Surg. 2015;67(4):389–400.

    Article  Google Scholar 

  58. Ramming KP, Sparks FC, Eilber FR, Holmes EC, Morton DL. Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. Am J Surg. 1976;132(2):236–42.

    Article  CAS  PubMed  Google Scholar 

  59. Reed ML, Vaitkevicius VK, Al-Sarraf M, Vaughn CB, Singhakowinta A, Sexon-Porte M, et al. The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: ten-year results of 124 patients in a prospective protocol. Cancer. 1981;47(2):402–9.

    Article  CAS  PubMed  Google Scholar 

  60. Kajanti M, Rissanen P, Virkkunen P, Franssila K, Mantyla M. Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study. Cancer. 1986;58(11):2386–8.

    Article  CAS  PubMed  Google Scholar 

  61. Shepherd FA, Evans WK, Blackstein ME, Fine S, Heathcote J, Langer B, et al. Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. J Clin Oncol. 1987;5(4):635–40.

    Article  CAS  PubMed  Google Scholar 

  62. Doci R, Bignami P, Bozzetti F, Bonfanti G, Audisio R, Colombo M, et al. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer. 1988;61(10):1983–7.

    Article  CAS  PubMed  Google Scholar 

  63. Patt YZ, Claghorn L, Charnsangavej C, Soski M, Cleary K, Mavligit GM. Hepatocellular carcinoma. A retrospective analysis of treatments to manage disease confined to the liver. Cancer. 1988;61(9):1884–8.

    Article  CAS  PubMed  Google Scholar 

  64. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95(3):588–95.

    Article  PubMed  Google Scholar 

  65. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol. 2002;80(3):143–8.

    Article  CAS  PubMed  Google Scholar 

  66. Sumie S, Yamashita F, Ando E, Tanaka M, Yano Y, Fukumori K, et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol. 2003;181(5):1327–34.

    Article  PubMed  Google Scholar 

  67. Amieva M, Peek RM Jr. Pathobiology of helicobacter pylori-induced gastric cancer. Gastroenterology. 2016;150(1):64–78.

    Article  CAS  PubMed  Google Scholar 

  68. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38(5):474–83.

    Article  CAS  PubMed  Google Scholar 

  69. Ikushima I, Higashi S, Seguchi K, Ishii A, Ota Y, Shima M, et al. Transarterial infusion chemotherapy with epirubicin in water-in-oil-in-water emulsion for recurrent hepatocellular carcinoma in the residual liver after hepatectomy. Eur J Radiol. 2009;69(1):114–9.

    Article  PubMed  Google Scholar 

  70. Kim HY, Kim JD, Bae SH, Park JY, Han KH, Woo HY, et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol. 2010;16(4):355–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Kim BK, Park JY, Choi HJ, Kim DY, Ahn SH, Kim JK, et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2011;137(4):659–67.

    Article  CAS  PubMed  Google Scholar 

  72. Inaba Y, Arai Y, Yamaura H, Sato Y, Najima M, Aramaki T, et al. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). Am J Clin Oncol. 2011;34(1):58–62.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Alvin J. Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, MO, USA

    Matthew S. Strand & Ryan C. Fields

Authors
  1. Matthew S. Strand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryan C. Fields
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryan C. Fields .

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, Winship Cancer Institute, Emory University Hospital Midtown, Atlanta, GA, USA

    Kenneth Cardona

  2. Division of Surgical Oncology, Winship Cancer Institute, Emory University Hospital, Atlanta, GA, USA

    Shishir K. Maithel

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Strand, M.S., Fields, R.C. (2018). Hepatic Artery Infusion Therapy for Primary Liver Tumors. In: Cardona, K., Maithel, S. (eds) Primary and Metastatic Liver Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-91977-5_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91977-5_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91976-8

  • Online ISBN: 978-3-319-91977-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation